Skip to main content

Table 2 The effect of the type of drug resistance or history of TB treatment on the culture conversion rate at month 6 of the two groups

From: Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China

Indicators

BDQ group (n = 102)

 

Non-BDQ group (n = 100)

 

p value

 

Conversion

Failed to conversion

Conversion

Failed to conversion

 

Type of drug resistance (n, %)

     

 RR

3 (100.0)

0 (0.0)

4 (80.0)

1 (20.0)

1.00

 MDR

65 (87.8)

9 (12.2)

50 (73.5)

18 (26.5)

0.03*

 XDR

22 (88.0)

3 (12.0)

18 (66.7)

9 (33.3)

0.07

History of TB treatment (n, %)

     

 New cases

10 (90.9)

1 (9.1)

6 (75.0)

2 (25.0)

0.55

 One-time history of TB treatment

34 (91.9)

3 (8.1)

19 (76.0)

6 (24.0)

0.17

 Two-time history of TB treatment

27 (84.4)

5 (15.6)

31 (81.6)

7 (18.4)

0.76

 ≥ Three-time history of TB treatment

19 (86.4)

3 (13.6)

16 (55.2)

13 (44.8)

0.02*

 MDR/RR-TB

(n = 77)

 

(n = 73)

  

 New cases

7(100.0)

0(0.0)

5 (71.4)

2 (28.6)

0.46

 One-time history of TB treatment

30 (90.9)

3 (9.1)

15 (71.4)

6 (28.6)

0.06

 Two-time history of TB treatment

19 (86.4)

3 (13.6)

23 (88.5)

3 (11.5)

0.83

 ≥ Three-time history of TB treatment

13 (86.7)

2 (13.3)

11 (57.9)

8 (42.1)

0.13

 XDR-TB

(n = 25)

 

(n = 27)

  

 New cases

3 (75.0)

1 (25.0)

1 (100.0)

0 (0.0)

1.00

 One-time history of TB treatment

4 (100.0)

0 (0.0)

4 (100.0)

0 (0.0)

 Two-time history of TB treatment

8 (80.0)

2 (20.0)

8 (66.7)

4 (33.3)

0.65

 ≥ Three-time history of TB treatment

6 (85.7)

1 (14.3)

5 (50.0)

5 (50.0)

0.30

  1. TB tuberculosis, n number, RR rifampicin-resistant, MDR multidrug-resistant, XDR extensively drug-resistant, BDQ bedaquiline
  2. * the differences had statistical significance (p < 0.05)